<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">Recurrent miscarriage</z:e> is the spontaneous loss of three or more consecutive pregnancies with the same biological father in the first trimester, and affects 1-2% of women, half of whom have no identifiable cause </plain></SENT>
<SENT sid="1" pm="."><plain>Overall, 75% of affected women will have a successful subsequent pregnancy, but this rate <z:hpo ids='HP_0002527'>falls</z:hpo> for older mothers and with increasing number of <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriages</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e>, with anticardiolipin or <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> antibodies, is present in 15% of women with recurrent first and second trimester <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriage</z:e> </plain></SENT>
<SENT sid="3" pm="?"><plain>METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for unexplained <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent miscarriage</z:e> </plain></SENT>
<SENT sid="4" pm="?"><plain>What are the effects of treatments for <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent miscarriage</z:e> caused by <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>We searched: Medline, Embase, The Cochrane Library and other important databases up to April 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review) </plain></SENT>
<SENT sid="6" pm="."><plain>We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: We found 14 systematic reviews, RCTs, or observational studies that met our inclusion criteria </plain></SENT>
<SENT sid="8" pm="."><plain>We performed a GRADE evaluation of the quality of evidence for interventions </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: aspirin (low dose), bed rest, <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, early scanning in subsequent pregnancies, <z:chebi fb="5" ids="28304">heparin</z:chebi> plus low-dose aspirin, human chorionic gonadotrophin, intravenous immunoglobulin treatment, lifestyle adaptation, <z:chebi fb="67" ids="50114">oestrogen</z:chebi>, paternal white cell immunisation, <z:chebi fb="28" ids="17026">progesterone</z:chebi>, trophoblastic membrane infusion, and vitamin supplementation </plain></SENT>
</text></document>